INDICATION

CLOSE

ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

ELIQUIS is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial therapy.

ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

See ELIQUIS Evidence

See select ELIQUIS RCT and RWE data to help inform formulary decisions.

ELIQUIS has been studied in 7 registrational RCTs, including 18,201 patients in ARISTOTLE and 5598 patients in AVERROES, and evaluated in several real-world effectiveness and safety analyses using a national sample of Medicare and commercial claims data.1-4

See how RWE can help
support your decision making

The Potential Role of RWE

Select clinical trial and RWE data
for health plan professionals

ELIQUIS Evidence

View common questions and answers about ELIQUIS real-world evidence

Frequently Asked Questions

RCTs=randomized controlled trials; RWE=real-world evidence.

References

1. ELIQUIS® (apixaban) Package Insert. Bristol-Myers Squibb Company, Princeton, NJ, and Pfizer Inc, New York, NY.

2. Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients [published correction appears in Stroke. 2020;51:e71. doi:10.0061/STR0000000000000227 and Stroke. 2020;51:e44. doi:10.00161/STR0000000000000218]. Stroke. 2018;49:2933-2944. doi:10.0061/STROKEAHA.118.020232

3. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):1-18. pii: e003725. doi:10.1161/JAHA.116.003725

4. Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017;33(9):1595-1604. doi:10.1080/03007995.2017.1345729